Structural MRI in Huntington's disease and recommendations for its potential use in clinical trials

Neuroscience and Biobehavioral Reviews

Volumn 37, Issue 3, 2013, Pages 480-490

  Georgiou Karistianis, Nellie ^a   Scahill, Rachael ^b   Tabrizi, Sarah J ^b   Squitieri, Ferdinando ^c   Aylward, Elizabeth ^d  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c IRCCS NEUROMED   (Italy)

^d SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

Author keywords

Biomarkers; Clinical trials; Huntington's disease; Neuroimaging; Volumetric analyses

Indexed keywords

BIOLOGICAL MARKER;

AMYGDALOID NUCLEUS; BASAL GANGLION; BRAIN ATROPHY; BRAIN CORTEX; BRAIN FUNCTION; BRAIN REGION; BRAIN SIZE; CEREBROSPINAL FLUID; CINGULATE GYRUS; CLINICAL EFFECTIVENESS; DISEASE ASSOCIATION; DISEASE COURSE; HIPPOCAMPUS; HUMAN; HUNTINGTON CHOREA; IMAGE ANALYSIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; REPRODUCIBILITY; REVIEW; SENSITIVITY ANALYSIS; STANDARDIZATION; THALAMUS; VOLUMETRY; WHITE MATTER;

BIOLOGICAL MARKERS; BRAIN; CLINICAL TRIALS AS TOPIC; HUMANS; HUNTINGTON DISEASE; MAGNETIC RESONANCE IMAGING;

EID: 84874527795     PISSN: 01497634     EISSN: 18737528     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2013.01.022     Document Type: Review

References (83)

1. Aylward E.H., Anderson N.B., Bylsma F.W., Wagster M.V., Barta P.E., Sherr M., Feeney J., Davis A., Rosenblatt A., Pearlson G.D., Ross C.A. Frontal lobe volume in patients with Huntington's disease. Neurology 1998, 50:252-258.
2. Aylward E.H., Brandt J., Codori A.M., Mangus R.S., Barta P.E., Harris G.J. Reduced basal ganglia volume associated with the gene for Huntington's disease in asymptomatic at-risk persons. Neurology 1994, 44:823-828.
3. Aylward E.H., Codori A.M., Barta P.E., Pearlson G.D., Harris G.J., Brandt J. Basal ganglia volume and proximity to onset in preclinical Huntington's disease. Archives of Neurology 1996, 53:1293-1296.
4. Aylward E.H., Codori A.M., Rosenblatt A., Sherr M., Brandt J., Stine O.C., Barta P.E., Pearlson G.D., Ross C.A. Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington's disease. Movement Disorders 2000, 15:552-560.
5. Aylward E.H., Li Q., Stine O.C., Ranen N., Sherr M., Barta P.E., Bylsma F.W., Pearlson G.D., Ross C.A. Longitudinal change in basal ganglia volume in patients with Huntington's disease. Neurology 1997, 48:394-399.
6. Aylward E.H., Liu D., Nopoulos P.C., Ross C.A., Pierson R.K., Mills J.A., Long J.D., Paulsen J.S. Striatal volume contributes to the prediction of onset of Huntington disease in incident cases. Biological Psychiatry 2012, 71:822-828.
7. Aylward E.H., Nopoulos P.C., Ross C.A., Langbehn D.R., Pierson R.K., Mills J.A., Johnson H.J., Magnotta V.A., Juhl A.R., Paulsen J.S. Longitudinal change in regional brain volumes in prodromal Huntington disease. Journal of Neurology, Neurosurgery and Psychiatry 2011, 82:405-410.
8. Aylward E.H., Sparks B.F., Field K.M., Yallapragada V., Shpritz B.D., Rosenblatt A., Brandt J., Gourley L.M., Liang K., Zhou H., Margolis R.L., Ross C.A. Onset and rate of striatal atrophy in preclinical Huntington disease. Neurology 2004, 63:66-72.
9. Aylward, E. Structural imaging in preclinical HD. Abstracts of the 39th Annual INS Meeting, Journal of the International Neuropsychological Society, 17 supplement S1, March 2011, p. 63.
10. Bechtel N., Scahill R.I., Rosas H.D., Acharya T., Van Den Bogaard S.J.A., Jauffret C., Say M.J., Sturrock A., Johnson H., Onorato C.E., Salat D.H., Durr A., Leavitt B.R., Roos R.A.C., Landwehrmeyer G.B., Langbehn D.R., Stout J.C., Tabrizi S.J., Reilmann R. Tapping linked to function and structure in premanifest and symptomatic Huntington disease. Neurology 2010, 75:2150-2160.
11. Beglinger L.J., Nopoulos P.C., Jorge R.E., Langbehn D.R., Mikos A.E., Moser D.J., Duff K., Robinson R.G., Paulsen J.S. White matter volume and cognitive dysfunction in early Huntington's disease. Cognitive and Behavioral Neurology 2005, 18:102-107.
12. Bohanna I., Georgiou-Karistianis N., Sritharan A., Asadi H., Johnston L., Churchyard A., Egan G. Diffusion tensor imaging in Huntington's disease reveals distinct patterns of white matter degeneration associated with motor and cognitive deficits. Brain Imaging and Behavior 2011, 5:171-180.
13. Brandt G.N., Bonelli R.M. Structural neuroimaging of the basal ganglia in schizophrenic patients: a review. Wiener Medizinische Wochenschrift 2008, 158:84-90.
14. Brandt J., Bylsma F.W., Aylward E.H., Rothlind J., Gow C.A. Impaired source memory in Huntington's disease and its relation to basal ganglia atrophy. Journal of Clinical and Experimental Neuropsychology 1995, 17:868-877.
15. Campodonico J.R., Aylward E., Codori A.M., Young C., Krafft L., Magdalinski M., Ranen N., Slavney P.R., Brandt J. When does Huntington's disease begin?. Journal of the International Neuropsychological Society 1998, 4:467-473.
16. Ciarmiello A., Cannella M., Lastoria S., Simonelli M., Frati L., Rubinsztein D.C., Squitieri F. Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington's disease. Journal of Nuclear Medicine 2006, 47:215-222.
17. Della Nave R., Ginestroni A., Tessa C., Giannelli M., Piacentini S., Filippi M., Mascalchi M. Regional distribution and clinical correlates of white matter structural damage in Huntington disease: a tract-based spatial statistics study. American Journal of Neuroradiology 2010, 31:1675-1681.
18. Douaud G., Gaura V., Ribeiro M.J., Lethimonnier F., Maroy R., Verny C., Krystkowiak P., Damier P., Bachoud-Levi A.C., Hantraye P., Remy P. Distribution of grey matter atrophy in Huntington's disease patients: a combined ROI-based and voxel-based morphometric study. NeuroImage 2006, 32:1562-1575.
19. Frost C., Kenward M.G., Fox N.C. Optimizing the design of clinical trials where the outcome is a rate. Can estimating a baseline rate in a run-in period increase efficiency?. Statistics in Medicine 2008, 27:3717-3731.
20. Gavazzi C., Nave R.D., Petralli R., Rocca M.A., Guerrini L., Tessa C., Diciotti S., Filippi M., Piacentini S., Mascalchi M. Combining functional and structural brain magnetic resonance imaging in Huntington disease. Journal of Computer Assisted Tomography 2007, 31:574-580.
21. Georgiou-Karistianis N. A peek inside the Huntington's brain: will functional imaging take us one step closer in solving the puzzle?. Experimental Neurology 2009, 220:5-8.
22. Georgiou-Karistianis N., Gray M.A., Domínguez D.J.F., Dymowski A.R., Bohanna I., Johnston L.A., Churchyard A., Chua P., Stout J.C., Egan G.F. Automated differentiation of pre-diagnosis Huntington's disease from healthy control individuals based on quadratic discriminant analysis of the basal ganglia: the IMAGE-HD study. Neurobiology of Disease 2013, 51:82-92.
23. Ginestroni A., Battaglini M., Diciotti S., Della Nave R., Mazzoni L.N., Tessa C., Giannelli M., Piacentini S., De Stefano N., Mascalchi M. Magnetization transfer MR imaging demonstrates degeneration of the subcortical and cortical gray matter in Huntington disease. American Journal of Neuroradiology 2010, 31:1807-1812.
24. Halliday G.M., McRitchie D.A., Macdonald V., Double K.L., Trent R.J., McCusker E. Regional specificity of brain atrophy in Huntington's disease. Experimental Neurology 1998, 154:663-672.
25. Harris G.J., Codori A.M., Lewis R.F., Schmidt E., Bedi A., Brandt J. Reduced basal ganglia blood flow and volume in pre-symptomatic, gene-tested persons at-risk for Huntington's disease. Brain 1999, 122:1667-1678.
26. Harris G.J., Pearlson G.D., Peyser C.E., Aylward E.H., Roberts J., Barta P.E., Chase G.A., Folstein S.E. Putamen volume reduction on magnetic resonance imaging exceeds caudate changes in mild Huntington's disease. Annals of Neurology 1992, 31:69-75.
27. Henley S.M., Wild E.J., Hobbs N.Z., Warren J.D., Frost C., Scahill R.I., Ridgway G.R., MacManus D.G., Barker R.A., Fox N.C., Tabrizi S.J. Defective emotion recognition in early HD is neuropsychologically and anatomically generic. Neuropsychologia 2008, 46:2152-2160.
28. Henley S.M.D., Ridgway G.R., Scahill R.I., Klöppel S., Tabrizi S.J., Fox N.C., Kassubek J. Pitfalls in the use of voxel-based morphometry as a biomarker: examples from Huntington disease. American Journal of Neuroradiology 2010, 31:711-719.
29. Henley S.M.D., Wild E.J., Hobbs N.Z., Scahill R.I., Ridgway G.R., MacManus D.G., Barker R.A., Fox N.C., Tabrizi S.J. Relationship between CAG repeat length and brain volume in premanifest and early Huntington's disease. Journal of Neurology 2009, 256:203-212.
30. Hersh S., Rosas H.D., Ferrante R.J. Neuropathology and Pathophysiology of Huntington's Disease 2004, McGraw-Hill, New York.
31. Hobbs N.Z., Barnes J., Frost C., Henley S.M.D., Wild E.J., Macdonald K., Barker R.A., Scahill R.I., Fox N.C., Tabrizi S.J. Onset and progression of pathologic atrophy in Huntington disease: a longitudinal MR imaging study. American Journal of Neuroradiology 2010, 31:1036-1041.
32. Hobbs N.Z., Henley S.M., Ridgway G.R., Wild E.J., Barker R.A., Scahill R.I., Barnes J., Fox N.C., Tabrizi S.J. The progression of regional atrophy in premanifest and early Huntington's disease: a longitudinal voxel-based morphometry study. Journal of Neurology, Neurosurgery and Psychiatry 2010, 81:756-763.
33. Hobbs N.Z., Pedrick A.V., Say M.J., Frost C., Dar Santos R., Coleman A., Sturrock A., Craufurd D., Stout J.C., Leavitt B.R., Barnes J., Tabrizi S.J., Scahill R.I. The structural involvement of the cingulate cortex in premanifest and early Huntington's disease. Movement Disorders 2011, 26:1684-1690.
34. Huntington Study Group Unified huntington's disease rating scale: reliability and consistency. Movement Disorders 1996, 11:136-142.
35. Ille R., Holl A.K., Kapfhammer H.P., Reisinger K., Schafer A., Schienle A. Emotion recognition and experience in Huntington's disease: is there a differential impairment?. Psychiatry Research 2011, 188:377-382.
36. Jech R., Klempir J., Vymazal J., Zidovska J., Klempirova O., Ruzicka E., Roth J. Variation of selective gray and white matter atrophy in Huntington's disease. Movement Disorders 2007, 22:1783-1789.
37. Jurgens C.K., Van De Wiel L., Van Es A.C.G.M., Grimbergen Y.M., Witjes-Ané M.N.W., Van Der Grond J., Middelkoop H.A.M., Roos R.A.C. Basal ganglia volume and clinical correlates in 'preclinical' Huntington's disease. Journal of Neurology 2008, 255:1785-1791.
38. Kassubek J., Juengling F.D., Ecker D., Landwehrmeyer G.B. Thalamic atrophy in Huntington's disease co-varies with cognitive performance: a morphometric MRI analysis. Cerebral Cortex 2005, 15:846-853.
39. Kipps C.M., Duggins A.J., Mahant N., Gomes L., Ashburner J., McCusker E.A. Progression of structural neuropathology in preclinical Huntington's disease: a tensor based morphometry study. Journal of Neurology, Neurosurgery and Psychiatry 2005, 76:650-655.
40. Kipps C.M., Duggins A.J., McCusker E.A., Calder A.J. Disgust and happiness recognition correlate with anteroventral insula and amygdala volume respectively in preclinical Huntington's disease. Journal of Cognitive Neuroscience 2007, 19:1206-1217.
41. Klöppel S., Chu C., Tan G.C., Draganski B., Johnson H., Paulsen J.S., Kienzle W., Tabrizi S.J., Ashburner J., Frackowiak R.S.J. Automatic detection of preclinical neurodegeneration: presymptomatic Huntington disease. Neurology 2009, 72:426-431.
42. Klöppel S., Draganski B., Golding C.V., Chu C., Nagy Z., Cook P.A., Hicks S.L., Kennard C., Alexander D.C., Parker G.J.M., Tabrizi S.J., Frackowiak R.S.J. White matter connections reflect changes in voluntary-guided saccades in pre-symptomatic Huntington's disease. Brain 2008, 131:196-204.
43. Magnotta V.A., Harris G., Andreasen N.C., O'Leary D.S., Yuh W.T.C., Heckel D. Structural MR image processing using the BRAINS2 toolbox. Computerized Medical Imaging and Graphics 2002, 26:251-264.
44. Majid D.A., Stoffers D., Sheldon S., Hamza S., Thompson W.K., Goldstein J., Corey-Bloom J., Aron A.R. Automated structural imaging analysis detects premanifest Huntington's disease neurodegeneration within 1 year. Movement Disorders 2011, 26:1481-1488.
45. Majid D.S., Aron A.R., Thompson W., Sheldon S., Hamza S., Stoffers D., Holland D., Goldstein J., Corey-Bloom J., Dale A.M. Basal ganglia atrophy in prodromal Huntington's disease is detectable over one year using automated segmentation. Movement Disorders 2011, 26:2544-2551.
46. Muhlau M., Weindl A., Wohlschlager A.M., Gaser C., Stadtler M., Valet M., Zimmer C., Kassubek J., Peinemann A. Voxel-based morphometry indicates relative preservation of the limbic prefrontal cortex in early Huntington disease. Journal of Neural Transplantation 2007, 114:367-372.
47. Nopoulos P., Magnotta V.A., Mikos A., Paulson H., Andreasen N.C., Paulsen J.S. Morphology of the cerebral cortex in preclinical Huntington's disease. American Journal of Psychiatry 2007, 164:1428-1434.
48. Nopoulos P.C., Aylward E.H., Ross C.A., Johnson H.J., Magnotta V.A., Juhl A.R., Pierson R.K., Mills J., Langbehn D.R., Paulsen J.S. Cerebral cortex structure in prodromal Huntington disease. Neurobiology of Disease 2010, 40:544-554.
49. Paulsen J.S., Langbehn D.R., Stout J.C., Aylward E., Ross C.A., Nance M., Guttman M., Johnson S., MacDonald M., Beglinger L.J., Duff K., Kayson E., Biglan K., Shoulson I., Oakes D., Hayden M. Detection of Huntington's disease decades before diagnosis: the predict-HD study. Journal of Neurology, Neurosurgery and Psychiatry 2008, 79:874-880.
50. Paulsen J.S., Magnotta V.A., Mikos A.E., Paulson H.L., Penziner E., Andreasen N.C., Nopoulos P.C. Brain structure in preclinical Huntington's disease. Biological Psychiatry 2006, 59:57-63.
51. Paulsen J.S., Nopoulos P.C., Aylward E., Ross C.A., Johnson H., Magnotta V.A., Juhl A., Pierson R.K., Mills J., Langbehn D., Nance M. Striatal and white matter predictors of estimated diagnosis for Huntington disease. Brain Research Bulletin 2010, 82:201-207.
52. Peinemann A., Schuller S., Pohl C., Jahn T., Weindl A., Kassubek J. Executive dysfunction in early stages of Huntington's disease is associated with striatal and insular atrophy: a neuropsychological and voxel-based morphometric study. Journal of the Neurological Sciences 2005, 239:11-19.
53. Politis M., Pavese N., Tai Y.F., Kiferle L., Mason S.L., Brooks D.J., Tabrizi S.J., Barker R.A., Piccini P. Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: a multimodal imaging study. Human Brain Mapping 2011, 32:258-270.
54. Rizk-Jackson A., Stoffers D., Sheldon S., Kuperman J., Dale A., Goldstein J., Corey-Bloom J., Poldrack R.A., Aron A.R. Evaluating imaging biomarkers for neurodegeneration in pre-symptomatic Huntington's disease using machine learning techniques. NeuroImage 2011, 56:788-796.
55. Rosas H.D., Goodman J., Chen Y.I., Jenkins B.G., Kennedy D.N., Makris N., Patti M., Seidman L.J., Beal M.F., Koroshetz W.J. Striatal volume loss in HD as measured by MRI and the influence of CAG repeat. Neurology 2001, 57:1025-1028.
56. Rosas H.D., Hevelone N.D., Zaleta A.K., Greve D.N., Salat D.H., Fischl B. Regional cortical thinning in preclinical Huntington disease and its relationship to cognition. Neurology 2005, 65:745-747.
57. Rosas H.D., Koroshetz W.J., Chen Y.I., Skeuse C., Vangel M., Cudkowicz M.E., Caplan K., Marek K., Seidman L.J., Makris N., Jenkins B.G., Goldstein J.M. Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis. Neurology 2003, 60:1615-1620.
58. Rosas H.D., Lee S.Y., Bender A.C., Zaleta A.K., Vangel M., Yu P., Fischl B., Pappu V., Onorato C., Cha J.H., Salat D.H., Hersch S.M. Altered white matter microstructure in the corpus callosum in Huntington's disease: implications for cortical " disconnection" NeuroImage 2010, 49:2995-3004.
59. Rosas H.D., Liu A.K., Hersch S., Glessner M., Ferrante R.J., Salat D.H., van der Kouwe A., Jenkins B.G., Dale A.M., Fischl B. Regional and progressive thinning of the cortical ribbon in Huntington's disease. Neurology 2002, 58:695-701.
60. Rosas H.D., Reuter M., Doros G., Lee S.Y., Triggs T., Malarick K., Fischl B., Salat D.H., Hersch S.M. A tale of two factors: what determines the rate of progression in Huntington's disease? A longitudinal MRI study. Movement Disorders 2011, 26:1691-1697.
61. Rosas H.D., Salat D.H., Lee S.Y., Zaleta A.K., Pappu V., Fischl B., Greve D., Hevelone N., Hersch S.M. Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity. Brain 2008, 131:1057-1068.
62. Rosas H.D., Tuch D.S., Hevelone N.D., Zaleta A.K., Vangel M., Hersch S.M., Salat D.H. Diffusion tensor imaging in presymptomatic and early Huntington's disease: selective white matter pathology and its relationship to clinical measures. Movement Disorders 2006, 21:1317-1325.
63. Ross C.A., Tabrizi S.J. Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurology 2011, 10:83-98.
64. Ruocco H.H., Bonilha L., Li L.M., Lopes-Cendes I., Cendes F. Longitudinal analysis of regional grey matter loss in Huntington disease: effects of the length of the expanded CAG repeat. Journal of Neurology, Neurosurgery and Psychiatry 2008, 79:130-135.
65. Ruocco H.H., Lopes-Cendes I., Li L.M., Cendes F. Evidence of thalamic dysfunction in Huntington disease by proton magnetic resonance spectroscopy. Movement Disorders 2007, 22:2052-2056.
66. Ruocco H.H., Lopes-Cendes I., Li L.M., Santos-Silva M., Cendes F. Striatal and extrastriatal atrophy in Huntington's disease and its relationship with length of the CAG repeat. Brazilian Journal of Medical and Biological Research 2006, 39:1129-1136.
67. Sanchez-Castaneda C., Cherubini A., Elifani F., Peran P., Orobello S., Capelli G., Sabatini U., Squitieri F. Seeking huntington disease biomarkers by multimodal, cross-sectional basal ganglia imaging. Human Brain Mapping 2012, 10.1002/hbm.22019.
68. Scahill R.I., Hobbs N.Z., Say M.J., Bechtel N., Henley S.M., Hyare H., Langbehn D.R., Jones R., Leavitt B.R., Roos R.A., Durr A., Johnson H., Lehéricy S., Craufurd D., Kennard C., Hicks S.L., Stout J.C., Reilmann R., Tabrizi S.J. Clinical impairment in premanifest and early Huntington's disease is associated with regionally specific atrophy. Human Brain Mapping 2013, 34:519-529.
69. Squitieri F., Cannella M., Simonelli M., Sassone J., Martino T., Venditti E., Ciammola A., Colonnese C., Frati L., Ciarmiello A. Distinct brain volume changes correlating with clinical stage, disease progression rate, mutation size, and age at onset prediction as early biomarkers of brain atrophy in Huntington's disease. CNS Neuroscience & Therapeutics 2009, 15:1-11.
70. Sritharan A., Egan G.F., Johnston L., Horne M., Bradshaw J.L., Bohanna I., Asadi H., Cunnington R., Churchyard A.J., Chua P., Farrow M., Georgiou-Karistianis N. A longitudinal diffusion tensor imaging study in symptomatic Huntington's disease. Journal of Neurology, Neurosurgery and Psychiatry 2010, 81:257-262.
71. Tabrizi S.J., Langbehn D.R., Leavitt B.R., Roos R.A., Durr A., Craufurd D., Kennard C., Hicks S.L., Fox N.C., Scahill R.I., Borowsky B., Tobin A.J., Rosas H.D., Johnson H., Reilmann R., Landwehrmeyer B., Stout J.C. Biological and clinical manifestations of huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurology 2009, 8:791-801.
72. Tabrizi S.J., Reilmann R., Roos R.A., Durr A., Leavitt B., Owen G., Jones R., Johnson H., Craufurd D., Hicks S.L., Kennard C., Landwehrmeyer B., Stout J.C., Borowsky B., Scahill R.I., Frost C., Langbehn D.R. Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurology 2012, 11:42-53.
73. Tabrizi S.J., Scahill R.I., Durr A., Roos R.A., Leavitt B.R., Jones R., Landwehrmeyer G.B., Fox N.C., Johnson H., Hicks S.L., Kennard C., Craufurd D., Frost C., Langbehn D.R., Reilmann R., Stout J.C. Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurology 2011, 10:31-42.
74. Thieben M.J., Duggins A.J., Good C.D., Gomes L., Mahant N., Richards F., McCusker E., Frackowiak R.S.J. The distribution of structural neuropathology in pre-clinical Huntington's disease. Brain 2002, 125:1815-1828.
75. Thu D.C., Oorschot D.E., Tippett L.J., Nana A.L., Hogg V.M., Synek B.J., Luthi-Carter R., Waldvogel H.J., Faull R.L. Cell loss in the motor and cingulate cortex correlates with symptomatology in Huntington's disease. Brain 2010, 133:1094-1110.
76. Van Den Bogaard S.J.A., Dumas E.M., Acharya T.P., Johnson H., Langbehn D.R., Scahill R.I., Tabrizi S.J., Van Buchem M.A., Van Der Grond J., Roos R.A.C. Early atrophy of pallidum and accumbens nucleus in Huntington's disease. Journal of Neurology 2011, 258:412-420.
77. Van Oostrom J.C.H., Maguire R.P., Verschuuren-Bemelmans C.C., Veenma-Van Der Duin L., Pruim J., Roos R.A.C., Leenders K.L. Striatal dopamine D2 receptors, metabolism, and volume in preclinical Huntington disease. Neurology 2005, 65:941-943.
78. Vandenberghe W., Demaerel P., Dom R., Maes F. Diffusion-weighted versus volumetric imaging of the striatum in early symptomatic Huntington disease. Journal of Neurology 2009, 256:109-114.
79. Vonsattel J.P., DiFiglia M. Huntington disease. Journal of Neuropathology and Experimental Neurology 1998, 57:369-384.
80. Vonsattel J.P., Myers R.H., Stevens T.J., Ferrante R.J., Bird E.D., Richardson E.P. Neuropathological classification of huntington's disease. Journal of Neuropathology and Experimental Neurology 1985, 44:559-577.
81. Weir D.W., Sturrock A., Leavitt B.R. Development of biomarkers for Huntington's disease. Lancet Neurology 2011, 10:573-590.
82. Wild E.J., Henley S.M., Hobbs N.Z., Frost C., MacManus D.G., Barker R.A., Fox N.C., Tabrizi S.J. Rate and acceleration of whole-brain atrophy in premanifest and early Huntington's disease. Movement Disorders 2010, 25:888-895.
83. Wolf R.C., Vasic N., Carlos S.-L., Ecker D., Landwehrmeyer G.B. Cortical dysfunction in patients with Huntington's disease during working memory performance. Human Brain Mapping 2009, 30:327-339.